stockportfolio.pro
Stocks / AXSM vs BBIO
AXSM vs BBIO
Axsome Therapeutics, Inc. and BridgeBio Pharma, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Axsome Therapeutics, Inc. (AXSM) | BridgeBio Pharma, Inc. (BBIO) | |
|---|---|---|
| Market cap | $13.0B | $13.3B |
| Revenue (latest FY) | $638.50M | $502.08M |
| Net income (latest FY) | $-183.17M | $-724.93M |
| Revenue growth (5y CAGR) | — | 127.4% |
| Net margin | -28.7% | -144.4% |
| Return on equity | -207.5% | 34.7% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open AXSM — free Open BBIO — freeFrequently asked questions
Which is bigger, AXSM or BBIO?
BridgeBio Pharma, Inc. is larger by market capitalization — $13.3B versus $13.0B.
Which grows faster, AXSM or BBIO?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.